Barcelona - Grifols (MCE: GRF, MCE: GRF.P y NASDAQ: GRFS), a global leader in the production of plasma-derived medicines with more than 100 years of history dedicated to enhancing people's health and well-being, closed a collaboration agreement with the U.S. firm ImmunoTek Bio Centers LLC, specialized in the opening and construction of plasma centers via strategic accords and contracts with healthcare companies. Through this accord, Grifols will accelerate the execution of its expansion plan and bolster its integrated network of plasma centers.

Grifols and ImmunoTek will combine their expertise for the development, construction and operation of 21 plasma collection centers with a capacity of 1 million liters of plasma per year.

Out of the total 21 centers in the agreement, 5 are already operating and are currently in the ramp-up phase. All 21 plasma collection centers will be established and functioning by October 2022. Grifols will have access to the plasma from the 5 centers in operation.

For Eduardo Herrero, President of Grifols Bioscience Industrial Group, "Plasma is one of the central pillars of Grifols' long-term, sustainable growth strategy. This agreement allows us to free up internal operating resources and focus on promoting, optimizing and expanding the capacity of our current plasma-center network, while working to open new centers with an exceptional partner like ImmunoTek."

ImmunoTek CEO Jerome Parnell III said, "This patnership continues ImmunoTek's aggressive expansion, and we are very pleased to have a leader like Grifols as a close partner."

Grifols remains committed to further expanding its plasma availability to meet anticipated robust demand and guarantee the supply of essential plasma therapies for patients who need them.

.

(C) 2021 M2 COMMUNICATIONS, source M2 PressWIRE